Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Clinical trial NCT04577014 · RECRUITING
Trial details
- NCT number
- NCT04577014
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-29
- Primary completion
- 2026-09-29
- Enrollment
- 98
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.